Date: September 29, 2025

Genmab A/S (Nasdaq: GMAB), the Danish biotech powerhouse, announced its intention to acquire Netherlands-based Merus N.V. (Nasdaq: MRUS) in an all-cash transaction valued at approximately $8.0 billion. This strategic move is set to significantly accelerate Genmab’s evolution into a global leader with a robust, wholly owned pipeline of oncology therapeutics, firmly positioning the company at the forefront of innovation in targeted cancer treatment.

Deal Overview and Strategic Rationale

Under the terms of the agreement, Genmab will acquire all outstanding shares of Merus for $97.00 each—representing a substantial premium of 41% over Merus’ pre-announcement closing price and about 44% over its recent 30-day volume-weighted average price. The acquisition, unanimously approved by both boards of directors, will be executed through a tender offer expected to close in Q1 2026, pending regulatory and shareholder approvals.

This deal underscores Genmab’s deliberate pivot from collaboration-heavy business models to one centered on wholly owned programs and assets. Currently, Genmab’s innovative pipeline features several key antibody-based therapeutics, but this acquisition marks a pivotal expansion. The addition of Merus’s pipeline, spearheaded by the Phase 3 asset petosemtamab, is anticipated to drive multiple new product launches by 2027, ensuring sustained growth and revenue diversity well into the next decade.

About the Key Asset: Petosemtamab

Central to this acquisition is petosemtamab, a first-in-class EGFRxLGR5 bispecific antibody designed for head and neck cancer—a notoriously challenging oncology indication. Petosemtamab stands out as an innovative immunotherapy, having secured two Breakthrough Therapy Designations (BTD) from the U.S. Food and Drug Administration (FDA) for first-line and second-line or greater recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). These designations underscore its potential to significantly improve upon the current standard of care.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, published Phase 2 data for petosemtamab demonstrated robust efficacy: patients exhibited both an impressive overall response rate and notably higher median progression-free survival compared to existing therapies, positioning the antibody as a likely best-in-class candidate. The therapy’s tolerability profile was favorable, bolstering hopes for improved patient outcomes with fewer debilitating side effects compared to traditional chemotherapy.

Development Pipeline and Market Potential

Merus is running two pivotal Phase 3 clinical trials evaluating petosemtamab for both first- and second/third-line HNSCC, with critical interim readouts anticipated in 2026. If these trials are successful, Genmab anticipates regulatory filings and a potential commercial launch as soon as 2027—a timeline in alignment with the company’s projection to transform its revenue profile with new wholly owned products.

Market analysts project the annual addressable market for advanced HNSCC therapies could exceed $5 billion worldwide, in large part due to high medical need and limited durable treatment options. Genmab forecasts that petosemtamab could achieve annual sales exceeding $1 billion by 2029, with multi-billion dollar revenue potential as its indications expand and further clinical results continue to deliver promise. The company also plans to explore additional indications and combination regimens, potentially leveraging petosemtamab’s bispecific targeting approach across broader cancer types.

The acquisition also brings Merus’ proprietary Multiclonics® platform, which enables the production of full-length human bispecific and trispecific antibodies, further bolstering Genmab’s research capabilities and augmenting its next-generation oncology portfolio.

Financial and Strategic Implications

Financing for the $8 billion transaction will be secured through a mix of Genmab’s cash reserves and approximately $5.5 billion in new non-convertible debt, underwritten by Morgan Stanley. Genmab remains confident in its ability to deleverage quickly, targeting a gross leverage ratio of under 3x within two years post-closing. The acquisition is forecast to become accretive to Genmab’s EBITDA by 2029, reflecting strong expected sales growth and the addition of high-margin, proprietary products.

Genmab’s latest guidance—unaffected by this announcement—reflects its current strong cash flow and commercial performance, with expansion driven by successful existing products such as Darzalex (co-commercialized with Johnson & Johnson) and a growing late-stage suite of antibody therapeutics. The Merus acquisition marks a commitment to sustain that trajectory well beyond the current decade.

Industry and Market Context

This acquisition arrives amid an uptick in biotech M&A activity throughout 2025, driven by a competitive market for breakthrough cancer therapies. Major pharmaceutical players such as Pfizer, Amgen, and AstraZeneca have all made large-scale acquisitions or partnerships within the oncology and immunotherapy sectors this year. Genmab’s aggressive pursuit of wholly owned assets reflects the broader industry trend of derisking clinical pipelines, seeking revenue diversification, and exercising greater strategic control over late-stage franchises that have blockbuster potential.

The focus on bispecific antibody technology, such as that pioneered by both Genmab and Merus, is particularly notable. These engineered molecules are at the cutting edge of cancer immunotherapy and are expected to drive the next wave of market growth. According to recent market reports, the global bispecific antibody sector is forecast to exceed $20 billion annually by the end of this decade, with significant contributions from both novel targets and improved clinical management of difficult-to-treat cancers.

Leadership Perspectives

“The proposed acquisition of Merus aligns with our long-term strategy to provide durable growth and accelerate our evolution as a leading biotechnology company,” said Jan van de Winkel, Ph.D., President and CEO of Genmab. “Petosemtamab may become a transformational therapy for patients with head and neck cancer— we look forward to leveraging our development and commercialization expertise to realize its full potential.”

Merus CEO Bill Lundberg, M.D., added, “We believe Genmab’s vision and experience can propel petosemtamab and other Multiclonics pipeline candidates to market, fulfilling our core mission of closing in on cancer with better medicines.”

Next Steps and Timeline

Upon successful completion of the tender offer, Merus will become a wholly owned subsidiary of Genmab. The timetable anticipates closure in early Q1 2026. Genmab will subsequently integrate Merus’s workforce, research platforms, and clinical programs, accelerating plans to launch petosemtamab and additional biospecific antibodies globally. Shareholders of Merus who do not tender immediately will be eligible for the same per-share consideration or a court-determined price, depending on post-offer corporate procedures.

Genmab will host an investor and media call to discuss the transaction today, with details and a webcast available on the company’s investor relations page. Investors are encouraged to monitor regulatory filings and further updates as integration proceeds.

About Genmab and Merus

Genmab is an international biotechnology company, founded in 1999 and headquartered in Copenhagen, Denmark, with a core mission to improve patient lives through innovative antibody therapeutics. With an emphasis on translational science, next-generation antibody platforms, and deep commercial partnerships, Genmab is recognized for its scientific rigor and successful global launches.

Merus, based in Utrecht, Netherlands, is a pioneer in multispecific antibody therapeutics—its Multiclonics platform enables the development of antibodies with greater versatility and potential for cancer and immune disease indications.

Conclusion

The acquisition of Merus by Genmab stands as a watershed moment in the biotech sector for 2025, exemplifying the industry’s shift toward focused, wholly owned oncology innovation. The deal’s success could have far-reaching implications—not just for the patients who may benefit from transformative therapies like petosemtamab, but for the competitive landscape of cancer drug development well into the next decade.